Company: DMAAR
Filing Date: 2025-05-20
Form Type: 10-Q
Source: 0001213900-25-046061
Chunk: 2

Company: Drugs Made In America Acquisition Corp.
Filing Date: 2025-05-20
Form: 10-Q
Item: Part I, Item 1
Chunk 2
---
 Balance — January 1, 2025

    9,857,143

    $
    986

    $
    —

    $
    34,014

    $
    (279,845
    )
     
    $
    (244,845
    )

    Sale of 430,000 Private Placement Units

    430,000

    43

    (1,100,000
    )

    4,299,957

    —

    3,200,000

    Fair value of representative shares

    230,000

    23

    —

    —

    —

    23

    Fair value of rights included in Public Units

    —

    —

    —

    3,424,700

    —

    3,424,700

    Allocated value of transaction costs to redeemable shares

    —

    —

    —

    (147,830
    )

    —

    (147,830
    )

    Expenses paid by the Sponsor

    —

    —

    247,621

    —

    —

    247,621

    Accretion for redeemable ordinary shares to redemption amount

    —

    —

    —

    (7,610,841
    )

    (7,299,721
    )

    (14,910,562
    )

    Net income

    —

    —

    —

    —

    1,254,543

    1,254,543

    Balance – March 31, 2025

    10,517,143

    $
    1,052

    $
    (852,379
    )
     
    $
    —

    $
    (6,325,023
    )
     
    $
    (7,176,350
    )

The accompanying notes are an integral part of
the unaudited financial statements.

3

DRUGS MADE IN AMERICA ACQUISITION CORP.

STATEMENT OF CASH FLOWS

FOR THE THREE MONTHS ENDED MARCH 31, 2025

(UNAUDITED)

    Cash Flows from Operating Activities: 

    Net income 
    $1,254,543 
  
    Adjustments to reconcile net income to net cash used in operating activities: 

    Payment of operation costs through promissory note 
     94,574 
  
    Interest earned on cash and investments held in Trust Account 
     (